Skip to main content

Gadopentetate dimeglumine and Alcohol/Food Interactions

There is 1 alcohol/food/lifestyle interaction with gadopentetate dimeglumine.

Major

Gadopentetate Dimeglumine High Blood Pressure (Hypertension)

Major Potential Hazard, Moderate plausibility

GBCAs - renal impairment

Gadolinium- based contrast agents (GBCAs) such as gadopentetate dimeglumine, gadoteridol and gadodiamide are contraindicated in patients with chronic, severe kidney disease (glomerular filtration rate, GFR < 30 mL/min), or acute kidney injury. GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Their use should be avoided in these patients unless the diagnostic information is essential and not available with non- contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs. Caution is advised in patients at risk for chronically reduced renal function (age >60 years, hypertension or diabetes). Always estimate the glomerular filtration rate (GFR) through laboratory testing.

References

  1. (2001) "Product Information. ProHance (gadoteridol)." Bracco Diagnostics Inc
  2. (2004) "Product Information. Omniscan (gadodiamide)." Novation
  3. (2005) "Product Information. Magnevist (gadopentetate dimeglumine)." Berlex Laboratories

Gadopentetate dimeglumine drug interactions

There are 41 drug interactions with gadopentetate dimeglumine.

Gadopentetate dimeglumine disease interactions

There are 3 disease interactions with gadopentetate dimeglumine which include:


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.